Table 2.
Correlation between MZB1 expression and the clinicopathological characteristics of the MTSCC patients
| Characteristics | No. of cases (%) | MZB1 | Fisher's exact test P value | |
|---|---|---|---|---|
| Low expression No. (%) | High expression No. (%) | |||
| Gender | ||||
| Female | 23 (71.9) | 8 (25.0) | 15 (46.9) | 1.000 |
| Male | 9 (28.1) | 3 (9.4) | 6 (18.7) | |
| T stage | ||||
| pT1 | 27 (84.4) | 7 (21.9) | 20 (62.5) | 0.037 |
| pT2 | 5 (15.6) | 4 (12.5) | 1 (3.1) | |
| pT3 | 0 | 0 | 0 | |
| Regional lymph nodes | ||||
| N0 | 32 (100) | 11 (34.4) | 21 (65.6) | * |
| N1 | 0 | 0 | 0 | |
| Distant metastasis | ||||
| M0 | 32 (100) | 11 (34.4) | 21 (65.6) | * |
| M1 | 0 | 0 | 0 | |
| Recurrence | ||||
| Positive | 32 (100) | 11 (34.4) | 21 (65.6) | * |
| Negative | 0 | 0 | 0 | |
| Clinical stage | ||||
| I | 27 (84.4) | 7 (21.9) | 20 (62.5) | 0.037 |
| II | 5 (15.6) | 4 (12.5) | 1 (3.1) | |
| III | 0 | 0 | 0 | |
*
No statistics were computed.